Genmab A (GMAB) Long-Term Deferred Tax (2019 - 2026)

Genmab A has reported Long-Term Deferred Tax for 6 years, with the latest figure at $173.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 34.11% year-over-year to $173.0 million; the trailing twelve-month figure through Mar 2026 stood at $173.0 million (up 34.11% YoY), and the FY2025 full-year result was $171.0 million, up 34.65% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $173.0 million, up from $171.0 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $173.0 million in Q1 2026, with the low at $31.0 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $126.4 million across 4 years, with a median of $127.0 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax soared 309.68% — and 2026, when it surged 34.11%.
• Genmab A's Long-Term Deferred Tax stood at $31.0 million in 2023, then soared by 309.68% to $127.0 million in 2024, then soared by 34.65% to $171.0 million in 2025, then advanced by 1.17% to $173.0 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $173.0 million (Q1 2026), $171.0 million (Q4 2025), and $127.0 million (Q3 2025), per Business Quant data.